Indian subsidiary of Colgate-Palmolive, dominant in oral care (toothpaste, toothbrushes) with a leading market share.
Indian subsidiary of Colgate-Palmolive, dominant in oral care (toothpaste, toothbrushes) with a leading market share.
Sells toothpaste, by far its largest product, through distributors who supply small shops across India including rural areas. The US parent owns a majority and is paid royalties for the brand and technology, a recurring cost.
In one line: Indian listed arm of Colgate-Palmolive.
Moat: wide (brand, distribution, installed base). Decades-long dominant market share in Indian oral care, deeply embedded in retail and rural distribution.
Headquarters: Mumbai, India · Founded: 1937 · Employees: 5,127
Size Colgate-Palmolive (India) (COLPAL.NS) is an India Consumer Staples company (Household/Personal Care) with a market value of $4.91B, the 216th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,688 on 18 Nov 2026.
Performance Over six months the shares fell 22.8%, against -2.5% for the median peer and +3.8% for the India market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 8.7% over the last twelve months (peer median +6.8%); the operating margin is 27.6% (peer median 13.2%).
Valuation It trades at 32.4× forward earnings against a peer median of 19.9× (5th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +27 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 13 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹63.9B | ₹60.4B | ₹60.4B | ₹56.8B | ₹52.3B |
| Revenue growth | — | 0% | +6% | +9% | — |
| Gross profit | ₹38.2B | ₹32.5B | ₹32.9B | ₹30.9B | ₹26.1B |
| EBITDA | ₹19.1B | ₹19.1B | ₹19.9B | ₹19.3B | ₹15.7B |
| Net income | ₹13.6B | ₹13.3B | ₹14.4B | ₹13.2B | ₹10.5B |
| Free cash flow | n/a | ₹17.9B | ₹13.9B | ₹11.9B | ₹11.4B |
| Capital expenditure | n/a | ₹765M | ₹714M | ₹756M | ₹701M |
| Total debt | ₹487M | ₹474M | ₹608M | ₹717M | ₹690M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Colgate-Palmolive (India) COLPAL.NS | $4.91B | -23% | +9% | 28% | 32.4× | 31.1% |
| Hindustan Unilever HINDUNILVR.NS | $50.0B | -11% | +6% | 21% | 41.4× | 27.4% |
| Dabur India DABUR.NS | $7.16B | -16% | +9% | 15% | 31.8× | 27.4% |
| Haleon HLN.L | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COLPAL.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.0% | 0.0% | 9th lowest of 21 |
| 6-month return | -22.8% | -2.5% | 3rd lowest of 21 |
| Distance from 52-week high | -26.6% | -21.0% | 9th lowest of 21 |
| Revenue growth (TTM) | +8.7% | +6.8% | 9th highest of 21 |
| Operating margin | 27.6% | 13.2% | 5th highest of 21 |
| Forward P/E | 32.4× | 19.9× | 5th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 31.1% | 2.2% | 2nd most demanding of 19 |
| Growth delivered (Del g) | +4.5% | +6.6% | 8th lowest of 19 |
| Hurdle (Req g minus delivered) | +26.6 pp | -2.6 pp | most demanding of 19 |
| EV / EBITDA | 23.2× | 13.2× | 5th most expensive of 18 |
| Net debt / EBITDA | -0.8× | -0.4× | 7th least indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Colgate-Palmolive (India) COLPAL.NS | India | $4.91B | -23% | +9% | 28% | 32.4× | 31.1% | +4.5% |
| Mao Geping Cosmetics 1318.HK | Hong Kong | $4.67B | -8% | +32% | 31% | 14.3× | 4.1% | +41.1% |
| Cupid CUPID.NS | India | $5.22B | +218% | +125% | 33% | n/a | n/a | n/a |
| Reynolds Consumer Products REYN | United States | $5.28B | +15% | +2% | 14% | 15.3× | 0.8% | +2.7% |
| Interparfums IPAR | United States | $4.28B | +48% | +3% | 18% | 28.4× | 10.5% | +22.5% |
| Amorepacific 090430.KS | South Korea | $6.01B | 0% | +10% | 9% | 24.4× | 3.6% | -0.8% |
| Rohto Pharmaceutical 4527.T | Japan | $3.87B | +8% | +7% | 12% | 16.5× | -2.8% | +13.7% |
| Lion 4912.T | Japan | $3.85B | +44% | +6% | 8% | 24.3× | 0.9% | +3.5% |
| Coty COTY | United States | $3.71B | +116% | 0% | 5% | 13.5× | 9.8% | +4.6% |
| APR 278470.KS | South Korea | $6.66B | -45% | +119% | 24% | 16.2× | -2.3% | +47.3% |
| e.l.f. Beauty ELF | United States | $6.73B | +124% | +40% | 14% | 34.3× | 24.1% | +38.8% |
| Dabur India DABUR.NS | India | $7.16B | -16% | +9% | 15% | 31.8× | 27.4% | +6.6% |
| Hengan Int'l 1044.HK | Hong Kong | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% | -0.1% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% | +1.9% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Godrej Consumer Products GODREJCP.NS | India | $9.75B | -12% | +12% | 18% | 39.1× | 32.9% | +6.6% |